BR9611320A - Composição farmacêutica - Google Patents

Composição farmacêutica

Info

Publication number
BR9611320A
BR9611320A BR9611320A BR9611320A BR9611320A BR 9611320 A BR9611320 A BR 9611320A BR 9611320 A BR9611320 A BR 9611320A BR 9611320 A BR9611320 A BR 9611320A BR 9611320 A BR9611320 A BR 9611320A
Authority
BR
Brazil
Prior art keywords
pct
pharmaceutical composition
date
sec
pub
Prior art date
Application number
BR9611320A
Other languages
English (en)
Other versions
BR9611320B1 (pt
Inventor
Angelo Guglielmotti
Paolo Dionisio
Original Assignee
Angelini Ricerche Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11372453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9611320(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angelini Ricerche Spa filed Critical Angelini Ricerche Spa
Publication of BR9611320A publication Critical patent/BR9611320A/pt
Publication of BR9611320B1 publication Critical patent/BR9611320B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
BRPI9611320-0A 1995-10-31 1996-10-26 composição farmacêutica compreendendo bidarit, um imunossurpressor selecionado a partir de ciclofosfamida, metilprednisolona, prednisolona e prednisona. BR9611320B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95MI002242A IT1276031B1 (it) 1995-10-31 1995-10-31 Composizione farmaceutica per il trattamento delle malattie autoimmuni
PCT/EP1996/004672 WO1997016185A2 (en) 1995-10-31 1996-10-26 A pharmaceutical composition for the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
BR9611320A true BR9611320A (pt) 1999-03-02
BR9611320B1 BR9611320B1 (pt) 2010-08-10

Family

ID=11372453

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9611320-0A BR9611320B1 (pt) 1995-10-31 1996-10-26 composição farmacêutica compreendendo bidarit, um imunossurpressor selecionado a partir de ciclofosfamida, metilprednisolona, prednisolona e prednisona.

Country Status (26)

Country Link
US (1) US6020356A (pt)
EP (1) EP0858337B1 (pt)
JP (1) JP4007615B2 (pt)
KR (1) KR19990067237A (pt)
CN (1) CN1229113C (pt)
AT (1) ATE326965T1 (pt)
AU (1) AU721841B2 (pt)
BR (1) BR9611320B1 (pt)
CA (1) CA2236256C (pt)
CZ (1) CZ292258B6 (pt)
DE (1) DE69636167T2 (pt)
DK (1) DK0858337T3 (pt)
EA (1) EA000826B1 (pt)
ES (1) ES2264144T3 (pt)
HU (1) HU228051B1 (pt)
IL (1) IL124291A (pt)
IT (1) IT1276031B1 (pt)
MX (1) MX9803478A (pt)
NO (1) NO324130B1 (pt)
NZ (1) NZ321580A (pt)
PL (1) PL186377B1 (pt)
PT (1) PT858337E (pt)
SK (1) SK284069B6 (pt)
TR (1) TR199800765T2 (pt)
WO (1) WO1997016185A2 (pt)
ZA (1) ZA969060B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
IT1293795B1 (it) 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
ATE445393T1 (de) * 2003-04-24 2009-10-15 Jagotec Ag Tablette mit gefärbtem kern
SG174026A1 (en) 2006-08-03 2011-09-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
AU2010207740B2 (en) * 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
SG176885A1 (en) 2009-08-03 2012-01-30 Acraf Process for the preparation of 1-benzyl-3-hydr0xymethyl-1h-indaz0le and its derivatives and required magnesium intermediates
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
EP3338776A1 (en) * 2012-05-01 2018-06-27 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
EP3990433B1 (en) 2019-06-25 2026-05-20 Translatum Medicus Inc PROCESSES FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015816A1 (en) * 1989-06-16 1990-12-27 The Upjohn Company Suramin type compounds and angiostatic steroids to inhibit angiogenesis
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
AU7376494A (en) * 1993-08-04 1995-02-28 Andrulis Pharmaceuticals Corporation Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
JPH10506632A (ja) * 1995-05-10 1998-06-30 ファイザー・インコーポレーテッド 慢性関節リウマチを治療するためのメトトレキセートとテニダップとの組合せ物

Also Published As

Publication number Publication date
CZ292258B6 (cs) 2003-08-13
CA2236256A1 (en) 1997-05-09
DK0858337T3 (da) 2006-09-18
JP4007615B2 (ja) 2007-11-14
WO1997016185A3 (en) 1997-07-03
MX9803478A (es) 1998-11-30
DE69636167D1 (de) 2006-06-29
SK57998A3 (en) 1998-12-02
PL186377B1 (pl) 2003-12-31
TR199800765T2 (xx) 1998-08-21
IT1276031B1 (it) 1997-10-24
NZ321580A (en) 2000-02-28
ITMI952242A1 (it) 1997-05-01
EA199800417A1 (ru) 1998-10-29
KR19990067237A (ko) 1999-08-16
ATE326965T1 (de) 2006-06-15
ES2264144T3 (es) 2006-12-16
HUP9901303A2 (hu) 1999-09-28
IL124291A (en) 2001-06-14
EP0858337A2 (en) 1998-08-19
AU7493896A (en) 1997-05-22
DE69636167T2 (de) 2007-03-29
NO981951L (no) 1998-06-29
CN1229113C (zh) 2005-11-30
ZA969060B (en) 1997-05-29
NO981951D0 (no) 1998-04-29
ITMI952242A0 (pt) 1995-10-31
HU228051B1 (en) 2012-09-28
AU721841B2 (en) 2000-07-13
JPH11515020A (ja) 1999-12-21
EA000826B1 (ru) 2000-04-24
BR9611320B1 (pt) 2010-08-10
NO324130B1 (no) 2007-09-03
CA2236256C (en) 2005-02-22
US6020356A (en) 2000-02-01
SK284069B6 (sk) 2004-09-08
WO1997016185A2 (en) 1997-05-09
HUP9901303A3 (en) 2001-04-28
CN1207042A (zh) 1999-02-03
CZ132698A3 (cs) 1998-10-14
EP0858337B1 (en) 2006-05-24
HK1018219A1 (en) 1999-12-17
PT858337E (pt) 2006-09-29
PL326371A1 (en) 1998-09-14

Similar Documents

Publication Publication Date Title
ES2128761T3 (es) Formulacion de tirilazad con cosolvente para administracion parenteral.
BG104620A (en) Oral pharmaceutical extended release dosage form
ES2179040T3 (es) Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
SE9504661D0 (sv) New compounds
PT871465E (pt) Utilizacao de ritonavir (abt-538) para melhorar a farmacocinetica de drogas metabolizadas por citocromo p450 num metodo de tratamento da sida
AU7491296A (en) The production of multilayer, solid drug forms for oral or rectal administration
NO954996L (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
DK0858337T3 (da) Farmaceutisk præparat til behandling af autoimmune sygdomme
DE69525649D1 (de) Lamotrigin haltiges arzneimittel
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
ATE319715T1 (de) Antikonvulsive pseudofructopyranose sulfamate
LV11728A (lv) Farmaceitiska kompozicija
NO20013414D0 (no) Ny anvendelse av melagatran
GEP20063719B (en) Prevention of Migraine Recurrence
CO4940452A1 (es) Modificacion a cristal de una sustancia activa de medicamen- to
ES2172182T3 (es) Composiciones farmaceuticas que comprenden cefuroxima axetil.
BG106151A (en) Pharmaceutical complex
WO1998014454A3 (en) (o-ACYL-p-N-ACYLAMINO-PHENYL)-O-PHOSPHOETHANOLAMINES
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.
SE9602262D0 (sv) New use of derivatives of cystine
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
SE9500897D0 (sv) The pharmacological use of certain cystine derivatives
WO1998038986A3 (en) Use of carvedilol or derivatives thereof for the manufacture of a medicament for the prevention and treatment of viral infections

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/08/2010, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061551/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO0132347-71.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. , ANGELINE RICERCHE S.PA SOCIETA CONSORTILE, ARDOZ PHARMA HOLDING IB.V, ASTRA AKTIEBOLAG, ASTRAZENECA AB, ASTRAZENECA UK LIMITED.